News

September 14, 2020

Rhythm Pharmaceuticals Appoints Yann Mazabraud as Executive Vice President, Head of International

September 9, 2020

Rhythm Pharmaceuticals to Present at Investor Conferences in September

August 6, 2020

Rhythm Pharmaceuticals to Present Virtually at Canaccord Genuity 40th Annual Growth Conference

August 3, 2020

Rhythm Pharmaceuticals Reports Second Quarter 2020 Financial Results

July 27, 2020

Rhythm Pharmaceuticals Announces Appointment of Joseph Shulman as Senior Vice President of Technical Operations

July 20, 2020

Rhythm Pharmaceuticals Announces Appointment of David Meeker, M.D., as Chief Executive Officer

July 16, 2020

Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide in Bardet-Biedl Syndrome in Diabetes, Obesity and Metabolism

July 1, 2020

Rhythm Pharmaceuticals Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Setmelanotide for Treatment of POMC and LEPR Deficiency Obesities

July 1, 2020

Rhythm Pharmaceuticals Announces Submission of Marketing Authorization Application to the European Medicines Agency for Setmelanotide in POMC and LEPR Deficiency Obesities

June 24, 2020

Rhythm Pharmaceuticals Announces Positive Results from Phase 2 Study of Once-weekly Formulation of Setmelanotide in Healthy Obese Volunteers

May 26, 2020

Rhythm Pharmaceuticals to Present Virtually at Upcoming Investor Conferences in June

May 13, 2020

Rhythm Pharmaceuticals Announces FDA Acceptance of New Drug Application for Setmelanotide for the Treatment of POMC and LEPR Deficiency Obesities

May 5, 2020

Rhythm Pharmaceuticals to Present Virtually at 2020 BofA Securities Health Care Conference

May 4, 2020

Rhythm Pharmaceuticals Reports First Quarter 2020 Financial Results

April 7, 2020

Rhythm Pharmaceuticals to Present Virtually at Needham & Co. 19th Annual Healthcare Conference

March 30, 2020

Rhythm Pharmaceuticals Provides Updates on Leadership Transition and Business Operations

March 30, 2020

Rhythm Pharmaceuticals Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Setmelanotide in POMC and LEPR Deficiency Obesities

March 18, 2020

Rhythm Pharmaceuticals Receives Orphan Drug Designation from U.S. FDA for Setmelanotide for the Treatment of Alström Syndrome

March 2, 2020

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results

February 25, 2020

Rhythm Pharmaceuticals to Present at Cowen & Co. 40th Annual Health Care Conference

January 6, 2020

Rhythm Pharmaceuticals Announces Leadership Transition